New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
08:11 EDTAMPEAmpio announces positive results from Ampion study
Ampio Pharmaceuticals announced the one month results of the open label portion of the multiple injections of Ampion into the knees of patients with osteoarthritis, or OA. Company explained "This first part of the multiple injections study involved patients receiving a series of three 4ml injections of Ampion intra-articularly. In order to proceed with the randomized vehicle- controlled portion of the trial, we had to repeat a demonstration of both safety and efficacy even though efficacy and safety had been demonstrated previously in the single injection SPRING study. No serious drug related adverse events were reported in either trial. The WOMAC A pain score improved by 65% from baseline with the multiple injections at one month post injection compared to 33% in the SPRING study at the same time point. In addition, the function score WOMAC C compared to baseline improved by 74 % at 4 weeks. The study also includes serial high resolution MRI's at various time points that will explore whether there are clinical benefits beyond pain relief."
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
18:18 EDTAMPERosewind acquires ProstaScint assets from Jazz Pharmaceuticals
In a regulatory filing earlier, Ampio Pharmaceuticals (AMPE) reported that on May 20, Rosewind, an approximately 81.5%-owned subsidiary of Ampio, entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals (JAZZ). Pursuant to the agreement, Rosewind purchased assets related to ProstaScint, or capromab pendetide, including certain intellectual property and contracts, and the product approvals, inventory and work in progress, and assumed certain of Jazz's liabilities, including those related to product approvals and the sale and marketing of ProstaScint. Rosewind paid $1M at closing for the ProstaScint assets. Rosewind has also agreed to pay an additional $500,000 within five days after transfer for the ProstaScint-related product inventory, and $226,523 payable on September 30, which represents a portion of certain United States Food and Drug Administration fees. Rosewind also will pay 8% on net sales made after October 31, 2017, payable up to a maximum aggregate payment of $2.5M. The agreement also provides that for a period of one year, Jazz agrees to not directly or indirectly, through any of its agents or affiliates, compete against ProstaScint, or acquire a company or business in which more than 15% of such acquired business’ total revenue is generated by products that compete with ProstaScint.
May 21, 2015
15:57 EDTAMPEAmpio says Optina benefit not significant vs. placebo, Bloomberg reports
Vaughan Lennox Clift, Chief Regulatory Affairs Officer of Ampio, told Bloomberg in a phone interview that Optina's benefit is not significant versus the placebo. Optina helped a group improve from baseline, Bloomberg adds. Clift also said the FDA may allow narrow sales with a post-market study.
08:08 EDTAMPEAmpio announces positive study results on Optima
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use